Compare NNBR & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNBR | BDTX |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.5M | 171.9M |
| IPO Year | 1996 | 2020 |
| Metric | NNBR | BDTX |
|---|---|---|
| Price | $3.31 | $1.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $3.00 | ★ $9.67 |
| AVG Volume (30 Days) | ★ 1.2M | 503.7K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.60 | ★ 130.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $770,657,000.00 | N/A |
| Revenue This Year | $8.60 | N/A |
| Revenue Next Year | $6.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $1.60 |
| 52 Week High | $4.48 | $4.94 |
| Indicator | NNBR | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.75 | 43.63 |
| Support Level | $3.29 | $1.61 |
| Resistance Level | $3.78 | $2.28 |
| Average True Range (ATR) | 0.17 | 0.09 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 19.69 | 12.70 |
NN Inc is a diversified industrial company that combines engineering and production capabilities with materials science expertise to design and manufacture high-precision components and solutions. The company operates through two segments: Mobile Solutions, which generates maximum revenue and focuses on the automotive, general industrial, and medical end markets, manufacturing tight-tolerance components used in battery electric, hybrid electric, and internal combustion engine vehicles, braking, transmissions, fuel systems, HVAC, and diesel systems; and Power Solutions, which focuses on the electrical, general industrial, automotive, medical, and aerospace and defense end markets and manufactures high-precision metal components, assemblies, contact assemblies, and precision stampings.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.